Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Under Armour Inc Class A (UA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Under Armour Inc Class A — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Under Armour Inc Class A trades at $6.54 (market cap $2.86B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.9× Under Armour Inc Class A's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | UA | |
|---|---|---|
Market Cap | $39.89B | $2.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $7.88 |
52-Week Low | $278.09 | $3.96 |
Enterprise Value | $38.15B | $4.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Under Armour (UA) trades at $6.61, up 2.48% with a bullish technical signal from moving averages. The company reported mixed Q1 2026 results with an EPS miss but maintains a 40.3% analyst buy rating. Recent financials show revenue of $5.16B for 2025 with negative net income of -$201.27M, though gross margins remain healthy at 45.48%. The Dodge collaboration and institutional buying by Prem Watsa provide positive catalysts amid ongoing business restructuring.
The outlook remains challenging with declining revenue projections and negative profitability metrics, but current valuation at 0.57 P/S offers potential for turnaround investors. Key risks include sustained revenue declines, competitive pressures, and negative cash flow trends. Institutional sentiment appears cautiously optimistic despite fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
